Cargando…

C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse

Extramedullary infiltration (EMI) is a concomitant manifestation that may indicate poor outcome of acute myeloid leukemia (AML). The underlying mechanism remains poorly understood and therapeutic options are limited. Here, we employed single-cell RNA sequencing on bone marrow (BM) and EMI samples fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Li-Xue, Zhang, Cheng-Tao, Yang, Meng-Ying, Zhang, Xue-Hong, Liu, Hong-Chen, Luo, Chen-Hui, Jiang, Yue, Wang, Zhang-Man, Yang, Zhong-Yin, Shi, Zhao-Peng, Yang, Yi-Ci, Wei, Ruo-Qu, Zhou, Li, Mi, Jun, Zhou, Ai-Wu, Yao, Zhi-Rong, Xia, Li, Yan, Jin-Song, Lu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651790/ https://www.ncbi.nlm.nih.gov/pubmed/36322939 http://dx.doi.org/10.1182/blood.2022017046

Ejemplares similares

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A global study for acute myeloid leukemia with RARG rearrangement
por: Zhu, Hong-Hu, et al.
Publicado: (2023)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling
por: Rethnam, Malini, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

ALCAM-EGFR interaction regulates myelomagenesis
por: Luo, Hongmei, et al.
Publicado: (2021)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment
por: Fei, Ming-Yue, et al.
Publicado: (2023)

TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice
por: Xie, Xiaoling, et al.
Publicado: (2023)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia
por: Song, Huan, et al.
Publicado: (2022)

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)

Enhancer remodeling drives MLL oncogene-dependent transcriptional dysregulation in leukemia stem cells
por: Pan, Feng, et al.
Publicado: (2023)

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
por: Saito, Kaori, et al.
Publicado: (2021)

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
por: Dunbar, Andrew J., et al.
Publicado: (2023)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression
por: Mu, Jiao, et al.
Publicado: (2022)

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
por: Li, Bin E., et al.
Publicado: (2023)

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
por: Dolinska, Monika, et al.
Publicado: (2023)

Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells
por: Chang, Yu-Tai, et al.
Publicado: (2023)

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
por: Borate, Uma, et al.
Publicado: (2023)

Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
por: Levy, Brynn, et al.
Publicado: (2022)

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

Patient-specific comorbidities as prognostic variables for survival in myelofibrosis
por: Sochacki, Andrew L., et al.
Publicado: (2022)

A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia
por: Ng, Stanley W. K., et al.
Publicado: (2022)

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
por: Perez, Monika W., et al.
Publicado: (2021)

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
por: Gorak, Edward J., et al.
Publicado: (2023)

Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions
por: DeZern, Amy E., et al.
Publicado: (2023)

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2022)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
por: McCarter, Joseph G. W., et al.
Publicado: (2023)

Long-term outcomes among adults with Langerhans cell histiocytosis
por: Goyal, Gaurav, et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3q6frbp79o1isbmhgl7ev4hv7d